Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Boudewijns, Steve ^a,b   Koornstra, Rutger H T ^a   Westdorp, Harm ^a,b   Schreibelt, Gerty ^b   van den Eertwegh, Alfons J M ^c   Geukes Foppen, Marnix H ^d   Haanen, John B ^d   de Vries, I Jolanda M ^a,b   Figdor, Carl G ^b   Bol, Kalijn F ^a,b   Gerritsen, Winald R ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c University of Amsterdam   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Dendritic cell vaccination; immunotherapy; ipilimumab; melanoma

Indexed keywords

IPILIMUMAB; LACTATE DEHYDROGENASE; TUMOR ANTIGEN;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; COLITIS; CONJUNCTIVITIS; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DERMATITIS; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOPHYSITIS; MALE; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PNEUMONIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SKIN BIOPSY; UVEITIS; VACCINATION; VITILIGO;

EID: 84981709947     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1201625     Document Type: Article

References (43)

1. J.Ferlay, E.Steliarova-Foucher, J.Lortet-Tieulent, S.Rosso, J.W.Coebergh, H.Comber, D.Forman, F.Bray. Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012. Eur J Cancer 2013; 49:1374-403; PMID:23485231; http://dx.doi.org/10.1016/j.ejca.2012.12.027
2. R.Dummer, D.Schadendorf, P.A.Ascierto, J.Larkin, C.Lebbe, A.Hauschild. Integrating first-line treatment options into clinical practice:what's new in advanced melanoma? Melanoma Res 2015; 25:461-9; PMID:26426764; http://dx.doi.org/10.1097/CMR.0000000000000200
3. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
4. C.Robert, L.Thomas, I.Bondarenko, S.O'Day, D.MDJ, C.Garbe, C.Lebbe, J.F.Baurain, A.Testori, J.J.Grob et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-26; PMID:21639810; http://dx.doi.org/10.1056/NEJMoa1104621
5. S.L.Topalian, M.Sznol, D.F.McDermott, H.M.Kluger, R.D.Carvajal, W.H.Sharfman, J.R.Brahmer, D.P.Lawrence, M.B.Atkins, J.D.Powderly et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020-30; PMID:24590637; http://dx.doi.org/10.1200/JCO.2013.53.0105
6. C.Robert, J.Schachter, G.V.Long, A.Arance, J.J.Grob, L.Mortier, A.Daud, M.S.Carlino, C.McNeil, M.Lotem et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
7. P.B.Chapman, A.Hauschild, C.Robert, J.B.Haanen, P.Ascierto, J.Larkin, R.Dummer, C.Garbe, A.Testori, M.Maio et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
8. C.Robert, B.Karaszewska, J.Schachter, P.Rutkowski, A.Mackiewicz, D.Stroiakovski, M.Lichinitser, R.Dummer, F.Grange, L.Mortier et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
9. J.Larkin, P.A.Ascierto, B.Dreno, V.Atkinson, G.Liszkay, M.Maio, M.Mandala, L.Demidov, D.Stroyakovskiy, L.Thomas et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371:1867-76; PMID:25265494; http://dx.doi.org/10.1056/NEJMoa1408868
10. S.Anguille, E.L.Smits, E.Lion, V.F.van Tendeloo, Z.N.Berneman. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
11. K.F.Bol, E.H.J.G.Aarntzen, F.E.M.in't Hout, G.Schreibelt, J.H.A.Creemers, W.J.Lesterhuis, W.R.Gerritsen, D.J.Grunhagen, C.Verhoef, C.J.A.Punt et al. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology 2016; 5:e1057673; PMID:26942068; http://dx.doi.org/10.1080/2162402X.2015.1057673
12. E.H.Aarntzen, K.Bol, G.Schreibelt, J.F.Jacobs, W.J.Lesterhuis, M.M.Van Rossum, G.J.Adema, C.G.Figdor, C.J.Punt, I.J.De Vries. Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma. Cancer Res 2012; 72:6102-10; PMID:23010076; http://dx.doi.org/10.1158/0008-5472.CAN-12-2479
13. E.H.Aarntzen, I.J.De Vries, W.J.Lesterhuis, D.Schuurhuis, J.F.Jacobs, K.Bol, G.Schreibelt, R.Mus, J.H.De Wilt, J.B.Haanen et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
14. K.Palucka, J.Banchereau. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013; 39:38-48; PMID:23890062; http://dx.doi.org/10.1016/j.immuni.2013.07.004
15. K.F.Bol, J.Tel, I.J.de Vries, C.G.Figdor. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; PMID:23802086; http://dx.doi.org/10.4161/onci.23431
16. K.F.Bol, C.G.Figdor, E.H.Aarntzen, M.E.Welzen, M.M.van Rossum, W.A.Blokx, M.W.van de Rakt, N.M.Scharenborg, A.J.de Boer, J.M.Pots et al. Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients. Oncoimmunology 2015; 4:e1019197; PMID:26405571; http://dx.doi.org/10.1080/2162402X.2015.1019197
17. T.F.Gajewski, Y.Meng, C.Blank, I.Brown, A.Kacha, J.Kline, H.Harlin. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006; 213:131-45; PMID:16972901; http://dx.doi.org/10.1111/j.1600-065X.2006.00442.x
18. A.M.Lesokhin, T.M.Hohl, S.Kitano, C.Cortez, D.Hirschhorn-Cymerman, F.Avogadri, G.A.Rizzuto, J.J.Lazarus, E.G.Pamer, A.N.Houghton et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012; 72:876-86; PMID:22174368; http://dx.doi.org/10.1158/0008-5472.CAN-11-1792
19. D.Schadendorf, F.S.Hodi, C.Robert, J.S.Weber, K.Margolin, O.Hamid, D.Patt, T.T.Chen, D.M.Berman, J.D.Wolchok. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33:1889-94; PMID:25667295; http://dx.doi.org/10.1200/JCO.2014.56.2736
20. T.Z.Horvat, N.G.Adel, T.O.Dang, P.Momtaz, M.A.Postow, M.K.Callahan, R.D.Carvajal, M.A.Dickson, S.P.D'Angelo, K.M.Woo et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33:3193-8; PMID:26282644; http://dx.doi.org/10.1200/JCO.2015.60.8448
21. L.Pierret, S.Wilgenhof, J.Corthals, T.Roelandt, K.Thielemans, B.Neyns. Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated with ipilimumab. J Clin Oncol 2009; 27; abstr e20006.
22. J.Yuan, B.Ginsberg, D.Page, Y.Li, T.Rasalan, H.F.Gallardo, Y.Xu, S.Adams, N.Bhardwaj, K.Busam et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma:three cases. Cancer Immunol Immunother 2011; 60:1137-46; PMID:21465316; http://dx.doi.org/10.1007/s00262-011-1011-9
23. J.Larkin, V.Chiarion-Sileni, R.Gonzalez, J.J.Grob, C.L.Cowey, C.D.Lao, D.Schadendorf, R.Dummer, M.Smylie, P.Rutkowski et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
24. B.Weide, S.Richter, P.Buttner, U.Leiter, A.Forschner, J.Bauer, L.Held, T.K.Eigentler, F.Meier, C.Garbe. Serum S100B, lactate dehydrogenase and brain metastasis are prognostic factors in patients with distant melanoma metastasis and systemic therapy. PloS one 2013; 8:e81624; PMID:24312329; http://dx.doi.org/10.1371/journal.pone.0081624
25. A.Y.Bedikian, M.M.Johnson, C.L.Warneke, N.E.Papadopoulos, K.Kim, W.J.Hwu, S.McIntyre, P.Hwu. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008; 26:624-33; PMID:18584354; http://dx.doi.org/10.1080/07357900802027073
26. S.Kelderman, B.Heemskerk, H.van Tinteren, R.R.van den Brom, G.A.Hospers, A.J.van den Eertwegh, E.W.Kapiteijn, J.W.de Groot, P.Soetekouw, R.L.Jansen et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014; 63:449-58; PMID:24609989; http://dx.doi.org/10.1007/s00262-014-1528-9
27. A.Martens, K.Wistuba-Hamprecht, M.H.Geukes Foppen, J.Yuan, M.A.Postow, P.Wong, E.Romano, A.Khammari, B.Dreno, M.Capone et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 2016; 22(12):2908-18; PMID:26787752; http://dx.doi.org/10.1158/1078-0432.CCR-15-2412
28. A.M.Eggermont, V.Chiarion-Sileni, J.J.Grob, R.Dummer, J.D.Wolchok, H.Schmidt, O.Hamid, C.Robert, P.A.Ascierto, J.M.Richards et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071):a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16:522-30; PMID:25840693; http://dx.doi.org/10.1016/S1470-2045(15)70122-1
29. E.H.Aarntzen, G.Schreibelt, K.Bol, W.J.Lesterhuis, A.J.Croockewit, J.H.de Wilt, M.M.van Rossum, W.A.Blokx, J.F.Jacobs, T.Duiveman-de Boer et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368
30. M.A.Morse, H.K.Lyerly. Checkpoint blockade in combination with cancer vaccines. Vaccine 2015; 33:7377-85; PMID:26482147; http://dx.doi.org/10.1016/j.vaccine.2015.10.057
31. A.van Elsas, A.A.Hurwitz, J.P.Allison. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190:355-66; PMID:10430624; http://dx.doi.org/10.1084/jem.190.3.355
32. F.Avogadri, R.Zappasodi, A.Yang, S.Budhu, N.Malandro, D.Hirschhorn-Cymerman, S.Tiwari, M.F.Maughan, R.Olmsted, J.D.Wolchok et al. Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies:therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer Immunol Res 2014; 2:448-58; PMID:24795357; http://dx.doi.org/10.1158/2326-6066.CIR-13-0220
33. S.Wilgenhof, J.Corthals, C.Heirman, N.van Baren, S.Lucas, P.Kvistborg, K.Thielemans, B.Neyns. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J Clin Oncol 2016; 34(12):1330-8; PMID:26926680; http://dx.doi.org/10.1200/JCO.2015.63.4121
34. T.N.Schumacher, R.D.Schreiber. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; http://dx.doi.org/10.1126/science.aaa4971
35. B.M.Carreno, V.Magrini, M.Becker-Hapak, S.Kaabinejadian, J.Hundal, A.A.Petti, A.Ly, W.R.Lie, W.H.Hildebrand, E.R.Mardis et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015; 348:803-8; PMID:25837513; http://dx.doi.org/10.1126/science.aaa3828
36. J.D.Wolchok, B.Neyns, G.Linette, S.Negrier, J.Lutzky, L.Thomas, W.Waterfield, D.Schadendorf, M.Smylie, T.Guthrie, Jr et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma:a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11:155-64; PMID:20004617; http://dx.doi.org/10.1016/S1470-2045(09)70334-1
37. S.J.O'Day, M.Maio, V.Chiarion-Sileni, T.F.Gajewski, H.Pehamberger, I.N.Bondarenko, P.Queirolo, L.Lundgren, S.Mikhailov, L.Roman et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma:a multicenter single-arm phase II study. Ann Oncol 2010; 21:1712-7; PMID:20147741; http://dx.doi.org/10.1093/annonc/mdq013
38. C.M.Balch, J.E.Gershenwald, S.J.Soong, J.F.Thompson, M.B.Atkins, D.R.Byrd, A.C.Buzaid, A.J.Cochran, D.G.Coit, S.Ding et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
39. D.H.Schuurhuis, P.Verdijk, G.Schreibelt, E.H.Aarntzen, N.Scharenborg, A.de Boer, M.W.van de Rakt, M.Kerkhoff, M.J.Gerritsen, F.Eijckeler et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res 2009; 69:2927-34; PMID:19318559; http://dx.doi.org/10.1158/0008-5472.CAN-08-3920
40. W.J.Lesterhuis, I.J.de Vries, G.Schreibelt, A.J.Lambeck, E.H.Aarntzen, J.F.Jacobs, N.M.Scharenborg, M.W.van de Rakt, A.J.de Boer, S.Croockewit et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261
41. J.Tel, E.H.Aarntzen, T.Baba, G.Schreibelt, B.M.Schulte, D.Benitez-Ribas, O.C.Boerman, S.Croockewit, W.J.Oyen, M.van Rossum et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75; PMID:23345163; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583
42. G.Schreibelt, K.F.Bol, H.Westdorp, F.Wimmers, E.H.Aarntzen, T.Duiveman-de Boer, M.W.van de Rakt, N.M.Scharenborg, A.J.de Boer, J.M.Pots et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res 2015; 22:2155-66; PMID:26712687; http://dx.doi.org/10.1158/1078-0432.CCR-15-2205
43. K.F.Bol, E.H.Aarntzen, J.M.Pots, M.A.Olde Nordkamp, M.W.van de Rakt, N.M.Scharenborg, A.J.de Boer, T.G.van Oorschot, S.A.Croockewit, W.A.Blokx et al. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunol Immunother 2016; 65:327-39; PMID:26861670; http://dx.doi.org/10.1007/s00262-016-1796-7